Questions arise about robotic surgery's cost, effectiveness
In the dozen years since the Da Vinci robot has been approved for surgeries in the United States, it's been embraced by health care providers and patients alike. Surgeons routinely use the multi-armed metal assistant to remove cancerous prostate glands and uteruses, repair heart valves and perform gastric bypass operations, among many other procedures. Lately a key study and reports of problems have raised questions about robotic surgery's safety and cost-effectiveness, leading to a review of the Da Vinci system by the Food and Drug Administration and causing some experts to wonder whether the benefits of undergoing robot-assisted surgery may have been overstated.
- How Top-Ranked MA Plans Earn Their Stars
- How Hospitals Can Become 'Upstreamists'
- Readmissions: No Quick Fix to Costly Hospital Challenge
- WellPoint Dominates Nearly Half of Markets, AMA Says
- CMS Offers Some ACOs $114M for 'Upfront' Costs
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- 4 Tips for Managing Employed Physicians
- Ebola: Second TX Nurse Diagnosed After Improper Protective Gear Application
- House Calls Key to Pioneer ACO Success
- Providers Ask HHS to Address EHR Interoperability Barriers